IL293544A - Methods for treating COPD by giving IL-33 antagonist - Google Patents

Methods for treating COPD by giving IL-33 antagonist

Info

Publication number
IL293544A
IL293544A IL293544A IL29354422A IL293544A IL 293544 A IL293544 A IL 293544A IL 293544 A IL293544 A IL 293544A IL 29354422 A IL29354422 A IL 29354422A IL 293544 A IL293544 A IL 293544A
Authority
IL
Israel
Prior art keywords
antagonist
administering
methods
treating copd
copd
Prior art date
Application number
IL293544A
Other languages
English (en)
Hebrew (he)
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of IL293544A publication Critical patent/IL293544A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL293544A 2019-12-06 2022-06-02 Methods for treating COPD by giving IL-33 antagonist IL293544A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962944878P 2019-12-06 2019-12-06
US202062964966P 2020-01-23 2020-01-23
US202063082502P 2020-09-24 2020-09-24
PCT/US2020/063404 WO2021113707A1 (en) 2019-12-06 2020-12-04 Methods for treating copd by administering an il-33 antagonist

Publications (1)

Publication Number Publication Date
IL293544A true IL293544A (en) 2022-08-01

Family

ID=74104197

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293544A IL293544A (en) 2019-12-06 2022-06-02 Methods for treating COPD by giving IL-33 antagonist

Country Status (12)

Country Link
US (1) US20210230265A1 (enExample)
EP (1) EP4069365A1 (enExample)
JP (2) JP7696900B2 (enExample)
KR (1) KR20220110553A (enExample)
CN (1) CN114786775A (enExample)
AU (1) AU2020398168A1 (enExample)
BR (1) BR112022010934A2 (enExample)
CA (1) CA3160521A1 (enExample)
IL (1) IL293544A (enExample)
MX (1) MX2022006812A (enExample)
TW (1) TW202134273A (enExample)
WO (1) WO2021113707A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021258255A1 (en) * 2020-04-22 2022-10-27 The Board Of Regents Of The University Of Texas System Medication return platform for extracting value from unused medications
TW202540173A (zh) * 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
WO2015057668A1 (en) * 2013-10-15 2015-04-23 Medimmune, Llc Methods for treating chronic obstructive pulmonary disease using benralizumab
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法

Also Published As

Publication number Publication date
CA3160521A1 (en) 2021-06-10
CN114786775A (zh) 2022-07-22
WO2021113707A1 (en) 2021-06-10
EP4069365A1 (en) 2022-10-12
BR112022010934A2 (pt) 2022-11-29
JP2025164767A (ja) 2025-10-30
MX2022006812A (es) 2022-08-25
JP2023505215A (ja) 2023-02-08
KR20220110553A (ko) 2022-08-08
AU2020398168A1 (en) 2022-07-28
US20210230265A1 (en) 2021-07-29
JP7696900B2 (ja) 2025-06-23
TW202134273A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
IL287275A (en) Methods of treating or preventing asthma by administering an IL-33 agonist
IL289930A (en) Methods for treating atopic dermatitis using an IL-4R antagonist
IL287907A (en) Cancer treatment methods
GB2587032B (en) Method for designing accelerator hardware
IL287617A (en) Hmgb1 antagonist
PT3107575T (pt) Métodos de tratamento e prevenção de asma administrando um antagonista de il-4r
IL286653A (en) Methods for treating muscular dystrophy with Casimersen
GB2598463B (en) Improved methods for angiography
IL289731A (en) Methods for treating or preventing asthma by administering an antagonist to il-4r
EP3265493A4 (en) Method of treating a localized fibrotic disorder using an il-33 antagonist
GB201907882D0 (en) Methods
PL3894407T3 (pl) Sposób wytwarzania apiksabanu
IL292502A (en) Therapeutic methods using vadadustat
IL277890B (en) Methods for quantifying il-33
GB201900789D0 (en) Method for testing time distribution
IL293544A (en) Methods for treating COPD by giving IL-33 antagonist
GB201906705D0 (en) Methods
IL284668A (en) Methods of treating schizophrenia
GB201918011D0 (en) Injector apparatus
GB201917998D0 (en) Injector apparatus
GB201918005D0 (en) Injector apparatus
GB201917994D0 (en) Injection apparatus
GB201900746D0 (en) Process for evaluating software elements within software
GB201900250D0 (en) Method for virus propagation
HK40082106A (en) Methods for treating copd by administering an il-33 antagonist